Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 07 Apr 2022
ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage
7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...
Posted by Michael Wonder on 07 Apr 2022
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
7 April 2022 - NICE has today issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or ...
Posted by Michael Wonder on 07 Apr 2022
A radical treatment for insulin pricing
6 April 2022 - A private, non-profit company recently announced that it intends to bypass the traditional supply chain and sell ...
Posted by Michael Wonder on 07 Apr 2022
TGA receives application for an increased dose of GlaxoSmithKline’s COVID-19 treatment sotrovimab (Xevudy) for the BA.2 omicron sublineage
7 April 2022 - The TGA has received an application from GSK for a higher (1,000 mg) dose of its ...
Posted by Michael Wonder on 07 Apr 2022
Hundreds of people with some forms of urothelial cancer to receive new treatment
7 April 2022 - Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new ...
Posted by Michael Wonder on 07 Apr 2022
Innovent announces the approval of Pemazyre (pemigatinib) by the NMPA for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement as confirmed by a validated diagnostic test that have progressed after at least one prior line of systemic therapy
6 April 2022 - Innovent Biologics announced that the National Medical Products Administration has approved Pemazyre (pemigatinib) for the treatment of ...
Posted by Michael Wonder on 07 Apr 2022
COVID-19 vaccine weekly safety report (7 April 2022)
7 April 2022 - To 3 April 2022, the TGA has received 511 reports which have been assessed as likely to ...
Posted by Michael Wonder on 07 Apr 2022
TGA approves yet another new medicine for patients with psoriasis
7 April 2022 - Bimekizumab is a humanised immunoglobulin G1 kappa monoclonal antibody. It has two identical antigen binding regions that ...
Posted by Michael Wonder on 07 Apr 2022
Dupixent (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
7 April 2022 - Approval based on Phase 3 data showing Dupixent significantly reduced severe asthma attacks and also improved lung ...
Posted by Michael Wonder on 07 Apr 2022
BeiGene announces European Medicines Agency acceptance of marketing authorisation applications for tislelizumab for the treatment of patients with ESCC and NSCLC
6 April 2022 - First European submissions for BeiGene’s anti PD-1 antibody licensed to Novartis for North America, Europe and ...
Posted by Michael Wonder on 06 Apr 2022
Some hoped FDA approval of Pfizer's COVID vaccine would convince unvaccinated Americans. It didn't, study finds.
6 April 2022 - After the Food and Drug Administration approved Pfizer-BioNTech’s COVID-19 vaccine in August, public health experts were ...
Posted by Michael Wonder on 06 Apr 2022
Eligible individuals can receive second COVID-19 booster shot at no cost
6 April 2022 - Today, the Centers for Medicare & Medicaid Services announced it will pay for a second COVID-19 booster ...
Posted by Michael Wonder on 06 Apr 2022
Inside a campaign to get Medicare coverage for a new Alzheimer’s drug
6 April 2022 - The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and ...
Posted by Michael Wonder on 06 Apr 2022
U.S. FDA aims to decide on strain selection for COVID boosters by June
6 April 2022 - The U.S. FDA said it is aiming to come up with a decision on coronavirus strain ...
Posted by Michael Wonder on 06 Apr 2022
BioXcel Therapeutics announces FDA approval of Igalmi (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults
6 April 2022 - U.S. commercial launch planned for Q2 2022. ...